

**A peer-reviewed version of this preprint was published in PeerJ on 9 May 2016.**

[View the peer-reviewed version](https://peerj.com/articles/cs-61) (peerj.com/articles/cs-61), which is the preferred citable publication unless you specifically need to cite this preprint.

Clark AM, Litterman NK, Kranz JE, Gund P, Gregory K, Bunin BA. 2016. BioAssay templates for the semantic web. PeerJ Computer Science 2:e61 <https://doi.org/10.7717/peerj-cs.61>

## BioAssay templates for the semantic web

Alex M Clark, Nadia K Litterman, Janice E Kranz, Peter Gund, Kellan Gregory, Barry A Bunin

Annotation of bioassay protocols using semantic web vocabulary is a way to make experiment descriptions machine-readable. Protocols are communicated using concise scientific English, which precludes most kinds of analysis by software algorithms. Given the availability of a sufficiently expressive ontology, some or all of the pertinent information can be captured by asserting a series of facts, expressed as semantic web triples (subject, predicate, object). With appropriate annotation, assays can be searched, clustered, tagged and evaluated in a multitude of ways, analogous to other segments of drug discovery informatics. The BioAssay Ontology (BAO) has been previously designed for this express purpose, and provides a layered hierarchy of meaningful terms which can be linked to. Currently the biggest challenge is the issue of content creation: scientists cannot be expected to use the BAO effectively without having access to software tools that make it straightforward to use the vocabulary in a canonical way. We have sought to remove this barrier by: (1) defining a bioassay template data model; (2) creating a software tool for experts to create or modify templates to suit their needs; and (3) designing a common assay template (CAT) to leverage the most value from the BAO terms. The CAT was carefully assembled by biologists in order to find a balance between the maximum amount of information captured vs. low degrees of freedom in order to keep the user experience as simple as possible. The data format that we use for describing templates and corresponding annotations is the native format of the semantic web (RDF triples), and we demonstrate some of the ways that generated content can be meaningfully queried using the SPARQL language. We have made all of these materials available as open source (<http://github.com/cdd/bioassay-template>), in order to encourage community input and use within diverse projects, including but not limited to our own commercial electronic lab notebook products.

# 1 **BioAssay Templates for the Semantic Web**

2

3 Alex M. Clark (corresponding author)

4 Nadia K. Litterman

5 Janice E. Kranz

6 Peter Gund

7 Kellan Gregory

8 Barry A. Bunin

9

## 10 **Abstract**

11 Annotation of bioassay protocols using semantic web vocabulary is a way to make experiment  
12 descriptions machine-readable. Protocols are communicated using concise scientific English,  
13 which precludes most kinds of analysis by software algorithms. Given the availability of a  
14 sufficiently expressive ontology, some or all of the pertinent information can be captured by  
15 asserting a series of facts, expressed as semantic web triples (subject, predicate, object). With  
16 appropriate annotation, assays can be searched, clustered, tagged and evaluated in a multitude  
17 of ways, analogous to other segments of drug discovery informatics. The BioAssay Ontology  
18 (BAO) has been previously designed for this express purpose, and provides a layered hierarchy  
19 of meaningful terms which can be linked to. Currently the biggest challenge is the issue of  
20 content creation: scientists cannot be expected to use the BAO effectively without having  
21 access to software tools that make it straightforward to use the vocabulary in a canonical way.  
22 We have sought to remove this barrier by: (1) defining a bioassay template data model; (2)  
23 creating a software tool for experts to create or modify templates to suit their needs; and (3)  
24 designing a common assay template (CAT) to leverage the most value from the BAO terms.  
25 The CAT was carefully assembled by biologists in order to find a balance between the  
26 maximum amount of information captured vs. low degrees of freedom in order to keep the user  
27 experience as simple as possible. The data format that we use for describing templates and  
28 corresponding annotations is the native format of the semantic web (RDF triples), and we  
29 demonstrate some of the ways that generated content can be meaningfully queried using the  
30 SPARQL language. We have made all of these materials available as open source  
31 (<http://github.com/cdd/bioassay-template>), in order to encourage community input and use  
32 within diverse projects, including but not limited to our own commercial electronic lab notebook  
33 products.

## 34 **Introduction**

35 One of the major problems currently being faced by biologists charged with the task of  
36 performing experimental assays on pharmaceutically interesting molecules is the information  
37 burden involved with handling collections of assay descriptions. Individual laboratories may  
38 carry out hundreds or even thousands of screening experiments each year. Each of these  
39 experiments involves a protocol, and any two experiments may be identical, similar, or  
40 completely different. The typical practice for describing bioassay protocols, for both external  
41 communication and internal record keeping, is to use concise scientific English, which is the

42 most universally human readable method of communication, assuming the recipient is familiar  
43 with the relevant jargon.

44 Unfortunately this method is not scalable. Even given the availability of an expert, it is often  
45 quite difficult and time-consuming to read two assay description paragraphs and provide a  
46 metric for the degree to which two protocols differ. There are many workflow scenarios where  
47 comparison of protocols is necessary, e.g. searching through a collection of previous  
48 experiments, or making a judgment call as to whether two batches of small molecule  
49 measurements are comparable. Attempting to use software to assist with such tasks, when the  
50 substrate is unconstrained text, results in solutions that are crude at best.

51 While these issues with scalability could be described as a relatively minor nuisance in a small  
52 laboratory, the field of drug discovery has lately been undergoing a renaissance of open data.<sup>1,2,</sup>  
53<sup>3,4</sup> Services such as PubChem provide a truly massive resource;<sup>5</sup> PubChem alone provides  
54 more than a million unique bioassay descriptions, and is growing rapidly.<sup>6,7</sup> Such data are  
55 supplemented by carefully curated resources like ChEMBL,<sup>8</sup> which are much smaller but have  
56 strict quality control mechanisms in place. What these services have in common is that their  
57 bioassay protocols have very little machine-readable content. In many cases, information about  
58 the target, and the kind and units of the measurements, have been abstracted out and  
59 represented in a marked up format, but all of the remaining particulars of the protocol are  
60 ensconced within English grammar, if at all.

61 In order to address this problem, the BioAssay Ontology (BAO) was devised.<sup>9,10,11</sup> The BAO,  
62 which includes relevant components from other ontologies, is a semantic web vocabulary that  
63 contains thousands of terms for biological assay screening concepts, arranged in a series of  
64 layered class hierarchies. The BAO is extensive and detailed, and easily extensible. The  
65 vocabulary is sufficiently expressive to be used for describing biological assays in a systematic  
66 way, yet it has seen limited use. Influential projects such as PubChem,<sup>12</sup> ChEMBL,<sup>13</sup> BARD<sup>14</sup>  
67 and OpenPHACTS<sup>15</sup> make use of the ontology, but the level of description in each is shallow,  
68 using only a small fraction of the terms.

69 There are a number of factors holding back scientists from using the BAO and related  
70 ontologies to describe their assays in detail, with perhaps the most substantial being the lack of  
71 software that makes the annotation process fast and convenient. Because it is based on the  
72 semantic web, BAO concepts are expressed as triples, of the form [*subject, predicate, object*].  
73 There are no hard rules about how this is applied, which is a characteristic of the semantic web,  
74 and is both an asset and a liability. The simplest way to consider annotating a particular feature  
75 of an assay, e.g. the biological process, is to compose a triple of a form such as [*assay ID,*  
76 *biological process, viral genome replication*]. Each of these 3 fields is a uniform resource  
77 indicator (URI), which points to a globally unique object with established meaning. In this case,  
78 *assay ID* would correspond to an identifier that the user has created for the assay description;  
79 *biological process* corresponds to a specific property in the BAO that is used to link assays and  
80 the biological process that is being affected; and *viral genome replication* refers to a class in the  
81 BAO, which identifies a specific instance of a biological process, which is in turn inherited from a  
82 sequence of increasingly general classes, and may also be linked to any other node within the  
83 greater semantic web, such as the extensive Gene Ontology (GO)<sup>16</sup>.

84 In principle, screening biologists can use the properties and classes from the BAO to annotate  
85 their assays intelligently in a machine readable format that is compatible with the universe of the  
86 semantic web. If large numbers of assays were sufficiently annotated, biologists and other drug  
87 discovery scientists could perform advanced searches and filtering that would enable better  
88 interpretation of results, enhanced building of machine-learning models, and uncovering of  
89 experimental artifacts. Despite the clear benefits of semantic annotation, the BAO remains

90 largely unused, the primary reason being its lack of accessibility. The BAO and its linked  
91 dependencies are large, and can be expected to keep growing as they are extended to capture  
92 more biological concepts. For an interactive view onto these terms, the site  
93 <http://bioportal.bioontology.org/ontologies/BAO> should be used to peruse the hierarchy.<sup>17</sup> Figure  
94 1 shows two snapshots of part of the BAO hierarchy, using the BioPortal resource. The *classes*  
95 (Figure 1a) that make up the ontology contain the bulk of the terms and provide most of the  
96 expressive value, while the *properties* (Figure 1b) are used to provide context. The class  
97 hierarchy is in places many levels deep, and although it is arranged in a logical pattern, it is  
98 nonetheless necessary to be familiar with the entire layout in order to meaningfully annotate an  
99 assay protocol. Even an expert biologist familiar with the entire ontology would be presented  
100 with multiple degrees of freedom for deciding how to annotate a protocol; this is a fundamental  
101 problem for machine readability, which requires uniform consistency.

102 In our previous work we addressed the end-user problem, and invented technology that applies  
103 to the scenario when a user is presented with plain English text, and is charged with the task of  
104 selecting the appropriate semantic annotations. Our solution involved a hybrid approach that  
105 combined natural language processing with machine learning based on training data, with an  
106 intuitive interface that helps the user select the correct annotations, leaving the final choice in  
107 the hands of the scientist.<sup>18</sup> During this process we found that the challenge that we were  
108 unable to fully overcome was the burden of creating new training data. The BAO vocabulary  
109 defines more than 2500 classes, in addition to properties and terms from other ontologies, all of  
110 which can be expected to grow as the BAO is increasingly used for more biological content.

111 Considering each term as it applies to a given assay requires a high level of expertise of the  
112 BAO itself. For example, the NIH's Molecular Libraries Program's bioassay database, known as  
113 the BARD, employed dedicated research staff to annotate more than two thousand assays.<sup>19</sup>  
114 The absence of clear and straightforward guidance as to which terms to use under what  
115 circumstances is preventing adoption of the BAO by drug discovery scientists. For our model  
116 building efforts, we made use of a training data set made up of 1066 PubChem bioassays that  
117 each had more than a hundred terms associated with them,<sup>20,21</sup> although not all of the  
118 annotations were able to be matched to ontology terms. For purposes of creating additional  
119 training data, we experienced considerable difficulty finding what we considered to be canonical  
120 annotations for any given assay.

121 The BAO is essentially a vocabulary that is capable of describing many assay properties, but it  
122 lacks instructions on its use. This is an issue that we have undertaken to solve, and in this  
123 article we describe our approach to providing this critical missing component.

124 We describe a data model called the BioAssay Template (BAT), which consists of a small  
125 number of terms which are organized to describe *how* the BAO and linked ontologies should be  
126 used to describe a particular kind of bioassay. A template is essentially a gateway to the overall  
127 ontology, which divides the assay annotation process into a fixed hierarchy of *assignments*,  
128 each of which has a prescribed list of *values*, which are cherry-picked from the overall ontology.

129 The BAT vocabulary can be used to create any number of templates, which can be customized  
130 to suit the task at hand. As a starting point, we have created what we refer to as the *common*  
131 *assay template* (CAT). CAT is an annotation recipe that is intended to capture the major  
132 properties that most biologists need to describe their assays and that enables most drug  
133 discovery scientists to have a basic understanding of an assay and its results.

134 A condensed summary of this template is shown in Figure 2. Unlike the class hierarchy of the  
135 BAO, the tree structure of the CAT is flat. While the data model allows groups and subgroups,  
136 our current template errs on the side of simplicity, and includes just 16 different assignments,

137 each of which is associated directly with the top-level assay, and each of which has a list of  
138 associated values (examples shown in Figure 2).

139 A template can be customized as necessary, and once it is ready, it can be used to define the  
140 way in which assays are annotated. The data model is designed to enable software to compose  
141 a user interface: presenting each of the categories, and making use of the selected values as  
142 the options that are made available to the user. It is essentially a way to restrict and simplify the  
143 large scope of the BAO, reduce the degrees of freedom, and remove ambiguity. Having curated  
144 the assignments and values so that the lists consist of the minimum number of relevant  
145 possibilities, each of them decorated by a meaningful label and a more detailed description, it  
146 becomes possible to design a user experience that is suitable for a scientist who is an expert in  
147 the field, but does not necessarily know anything about semantic web concepts.

148 In order to explore this approach, we have created a software package called the BioAssay  
149 Schema Editor, which is open source and available via GitHub. It is written using Java 8, and  
150 runs on the major desktop platforms (Windows, Mac & Linux). The software implements the  
151 data model that we describe in this article.

152 Our priorities for this work are to: (1) establish a data model for bioassay templates; (2) create  
153 an intuitive software package for editing these templates and using them to annotate real data;  
154 and (3) collaboratively establish a CAT for general purpose use. We have put a considerable  
155 amount of effort into the user interface for editing templates, even though we expect only a  
156 small fraction of biologists will ever be directly involved in editing them. We have also invested  
157 significant effort towards developing a one-size-fits-most template, the CAT. Our goal with the  
158 CAT was to enable capture of ~80% of the most commonly used terms, and present them in a  
159 logical and concise way, so that a large proportion of users will be able to use it as-is to add a  
160 significant amount of value to their protocol data. In addition, the CAT can act as a starting point  
161 for modification if scientists would like to tailor the template.

162 Scientists working in research groups that routinely make use of terms that are not included in  
163 the CAT can elect to start with an existing template and add the missing assignments and  
164 values, and also delete whole groups of content that do not apply to their research. A research  
165 group may accumulate a collection of task-specific templates, allowing their scientists to pick the  
166 most appropriate one. By ensuring that the editor software is easy to use, runs on all platforms,  
167 and is open source, we hope to ensure that this option is quite practical for any research group  
168 with access to basic information technology expertise. We intend to encourage the community  
169 to make use of these resources, both as standalone tools and interoperating with the electronic  
170 lab notebook software that we are presently designing.

171 One of the implicit advantages of using semantic web technology as the underlying data format  
172 (triples), and a well established set of reference terms (the BAO and various linked ontologies),  
173 is that even if two scientists are annotating assays with different templates, it is highly likely that  
174 many or most of the terms will overlap, even if the templates were created from scratch. Since  
175 the final deliverable for an annotated assay is the semantic web, it means that the output can be  
176 subjected to the entire universe of software designed to work with RDF triple stores.<sup>22</sup> As more  
177 assays are annotated, the scope and power of queries and informatics approaches for  
178 enhancing drug discovery projects are similarly increased. With a large corpus of annotated  
179 assays available, scientists will be able to make better use of prior work for understanding  
180 structure activity relationships, uncovering experimental artifacts, building machine-learning  
181 models, and reducing duplicated efforts.



## 182 **Methods**

### 183 **Data Model**

184 The semantic description of templates and annotations uses a small number of additional URIs,  
185 each of which has the root stem <http://bioassayontology.org/bat>, and is denoted using the  
186 Turtle-style<sup>23</sup> abbreviated prefix "bat".

187 The hierarchical model for describing a template is shown in Figure 3. Parent:child relationships  
188 denoted by an arrow indicate one-to-many relationships, while the properties listed in the boxes  
189 underneath the nodes are one-to-one relationships. A template definition begins with the *root*,  
190 which is distinguished by being of type `bat:BioAssayTemplate`. The root is also of type  
191 `bat:Group`, and has some number of child nodes, which are themselves either assignments or  
192 subgroups.

193 An assignment node has several scalar properties, including label and description, and it also  
194 refers to a *property* resource. These are typically mapped to URI resources found within the  
195 BAO (e.g. [http://www.bioassayontology.org/bao#BAO\\_0000205](http://www.bioassayontology.org/bao#BAO_0000205), label: "has assay format").  
196 Each assignment has some number of values associated with it, and these make up the list of  
197 available options. Each value is primarily identified by the resource that it maps to, which is  
198 typically found in the BAO (e.g. [http://www.bioassayontology.org/bao#BAO\\_0000219](http://www.bioassayontology.org/bao#BAO_0000219), label:  
199 "cell based format"). Besides the label and description, which are customizable within the  
200 template data model, the reference URI has its own implied class hierarchy (e.g. "cell based  
201 format" is a subclass of "assay format"), which is not encoded in the template data model, but is  
202 inferred once it is paired with the BAO and its linked ontologies.

203 The schema for annotation of assays is shown in Figure 4. The assay is given a distinct URI,  
204 and is associated with several properties such as label and description. The template is  
205 recorded, as is an optional reference to the origin of the assay (which may be a semantic web  
206 resource, or a DOI link to a journal article). The free-text description of the assay can also be  
207 recorded using the *hasParagraph* predicate.

208 The assay is associated with some number of annotations, which are primarily linked to  
209 assignments within the corresponding template. For annotations that assert a URI link, the  
210 *hasValue* predicate typically corresponds to one of the available values that was prescribed for  
211 the assignment in the template definition, and generally refers to a term defined in the BAO,  
212 though custom references can be used - or the annotation may be specified using the *hasLiteral*  
213 predicate instead, which means that the user has entered data in a different form, typically text  
214 or a numeric value. The *hasProperty* predicate is generally copied from the corresponding  
215 assignment.

216 When annotating an assay, each assignment may be used any number of times, i.e. zero  
217 instances means that it has been left blank, while asserting two or more triples means that all of  
218 the values apply. The relationship between assays and annotations has no nesting: the intrinsic  
219 group/sub-group structure of any particular annotation can be inferred from the template, since  
220 the *usesTemplate* and *isAssignment* predicates refer to the origins in the template.

### 221 **Software**

222 The BioAssay Schema Editor is available from GitHub ([https://github.com/cdd/bioassay-](https://github.com/cdd/bioassay-template)  
223 [template](https://github.com/cdd/bioassay-template)) and may be used under the terms of the Gnu Public License 2.0.<sup>24</sup> The code is written  
224 using Java 8, and the user interface is based on JavaFX. Semantic web functionality is  
225 implemented by incorporating the Apache Jena library.<sup>25</sup> The project includes a snapshot of the  
226 BioAssay Ontology<sup>26</sup> and some of the linked ontologies, as well as the latest version of the

227 common assay template schema. It should be assumed that the project will continue to evolve  
228 until well after the publication date of this article.

229 The application operates on a datafile referred to as a *schema*, which is represented as a  
230 collection of triples (in Turtle format, with the extension .ttl). A schema is expected to include a  
231 single template, for which the root node is of type bat:BioAssayTemplate, and may optionally  
232 contain any number of assays that have been (or will be) annotated using that same template.  
233 Triples are used as the serialization format in order that the editable files can be used as-is by a  
234 Triple store, and become a part of the semantic web with no further modification.

235 Figure 5 shows the main window for the application, which has loaded a contemporary version  
236 of the *common assay template (CAT)*, and has several accompanying assays awaiting  
237 annotation. The components that make up the template are shown as a hierarchy on the left  
238 hand side of the panel. Selecting any of the groups or assignments causes the detail view on  
239 the right to be filled in with the corresponding content.

240 Adding, deleting, renaming etc. of groups, assignments and values is fairly mundane, and  
241 follows standard desktop user interface design patterns. Selecting URI values for properties and  
242 values requires a more specific interface, and is composed by summarizing the BAO  
243 vocabulary, which is loaded into the application at the beginning. Resources can be selected  
244 using a dialog box that can present the list of options in a flat list, with an optional search box for  
245 restricting the list (Figure 6a) or by using the hierarchy view that shows the position in the BAO  
246 ontology (Figure 6b). The dialog box can also be used to add multiple values at once, which is  
247 particularly convenient when a branch of the BAO encompasses multiple terms that are all valid  
248 options. When a resource is selected, its label and description are imported from the BAO into  
249 the template: these values can be edited after the fact, but by default they are the same as in  
250 the underlying vocabulary.

251 The primary role of the schema editor is to provide a convenient way to edit templates, but in  
252 support of this goal, it also provides an interface to use the template to annotate assays. The  
253 interface can be used for generating training data (e.g. for model generation), but it is mainly  
254 intended as a way to 'test drive' the current template. Because the annotation process is directly  
255 derived from the template, having the two editing processes side by side is advantageous when  
256 the template is being designed. For example, the operator can begin annotating an assay, and if  
257 a value is missing from one of the assignments, or a new kind of assignment turns out to be  
258 necessary, this can be added to the template within the same editing session.

259 Figure 7a shows an example of an assay that has been annotated. The detail view has a  
260 placeholder for description text, which is particularly useful when the content has been imported  
261 from some external source, and the annotations are being made by converting the protocol text  
262 into semantic annotations. Clicking on any of the annotation buttons brings up a panel of options  
263 (Figure 7b) that represent the prescribed values for the assignment. Each of the assignments  
264 can be left blank, annotated once, or given multiple values. The ideal use case is when the  
265 value (or values) occurs within the list of prescribed values, but since the data model allows any  
266 URI, the user interface also allows the user to insert a custom URI. In cases where no URI is  
267 listed in the template (e.g. a concept that does not have an established URI), it is possible to  
268 add plain text for any of the assignment annotations. While this has no meaning from a  
269 machine-learning point of view, it can serve as a convenient placeholder for terms that will be  
270 invented in the future.



## 271 Results

### 272 Templates

273 We set out to create a common assay template (CAT) that includes the basic details essential to  
274 defining any bioassay: assay type, format, target and biology, results and pharmacology, and  
275 other details. The CAT was developed with the opposing goals of identifying assignments that  
276 (1) would be limited in number in order to be not overly burdensome vs. (2) comprehensively  
277 cover the majority of the information contained in written descriptions of bioassays. We also  
278 considered the type of information that would be utilized by an end user attempting to search,  
279 filter, and aggregate assays by their bioassay annotations. For example, details such as the  
280 assay footprint (plate type), assay kit, and detection instrument were included because they  
281 may be useful terms for identifying experimental artifacts. Biological process and other target-  
282 related information were included to enable aggregating results across similar drug discovery  
283 projects for model-building and other applications. Finally, we limited assignments to those  
284 where the BAO offered sufficient options for possible values. Since the goal of the project is to  
285 generate machine-readable assay annotations, we avoided assignments where BAO terms  
286 were not available, such as those characterizing *in vivo* assays, and especially assignments  
287 whose values would be very specific for each assay, such as negative and positive controls.  
288 These areas will be addressed in the future once the underlying vocabulary (BAO or otherwise)  
289 is available sufficient to expand the domain. Similarly, the CAT falls short of capturing detailed  
290 protocol steps. In its present incarnation, it cannot be considered as a complete replacement for  
291 the text that is typically used to describe an assay, though we do intend to pursue this level of  
292 detail in future work. For the present, we are primarily concerned with utilizing the rich  
293 vocabulary within the BAO to achieve maximum impact with minimum additional burden on the  
294 end user workflow.

295 To develop the CAT, we used the following process: first, biologists independently considered  
296 each of the terms available in the BAO and prioritized assignments for the CAT. Each  
297 assignment was associated with a number of possible values based on the BAO hierarchy.  
298 Then, quantitative and qualitative approaches were used to determine if the prioritized  
299 assignments included in the CAT were sufficient to fully describe most assays. For the  
300 quantitative approach, we assessed the set of 1066 PubChem bioassays<sup>27</sup> that were previously  
301 annotated by hand by BAO experts.<sup>28</sup> In that exercise, the BAO experts aimed to fully annotate  
302 each assay, capturing all applicable information for more than a hundred different categories or  
303 terms. If there was not an applicable value, the assignment or category was left blank. We  
304 analyzed the use of the BAO terms to assess the utility and comprehensiveness of the  
305 assignments included in the CAT compared to the remaining terms. We found that the 16 CAT  
306 assignments were annotated in 81% of the 1066 PubChem assays compared to 33% for the  
307 remaining terms. We also found that 95% of the values for CAT assignments were BAO terms  
308 rather than literal or non-URI based terms, compared to 63% in the remaining categories. These  
309 results suggested that the CAT includes assignments that are both relevant to the majority of  
310 assays as represented in PubChem and well covered by the BAO.

311 For an in-depth qualitative assessment of the CAT, biologists annotated a wide variety of  
312 assays, encompassing different assay types (e.g., cell viability, enzyme activity, binding, and  
313 ADMET), assay formats (e.g., cell-based, biochemical, microsome, organism, tissue, etc.), and  
314 assay design methods (e.g., ATP quantitation, cell number, immunoassays, gene expression,  
315 radioligand binding, etc), as summarized in Table 1. We found that in many cases, both from  
316 assay descriptions available from PubChem and from in-house screening assay descriptions,  
317 the CAT captured much of the relevant information. For example, annotating an assay for cell  
318 viability (PubChem ID 427) shows that all but two of the 16 CAT assignments are readily

319 annotated from the short descriptive information provided (Figure 8). 'Target' is left blank, as it is  
320 not applicable (this assay aims solely to identify cytotoxic compounds); 'Detection Instrument'  
321 was not noted. Similarly, as shown in Figure 9, all applicable CAT assignments (15 of the 16)  
322 are annotated from the description of a competitive binding assay (PubChem ID 440). Figure 9  
323 also illustrates that multiple values can be annotated for a single assignment, enabling content  
324 from complex assays to be captured. Together, these two examples highlight that both cell-  
325 based and biochemical assays can be extremely well-suited to be annotated using the CAT.

326 However, there were some cases where the CAT was less effective in capturing important  
327 information. For example, 14 of the 16 CAT assignments could be annotated for PubChem ID  
328 488847, some with multiple values; however, the 'big picture' view of this rather complex  
329 primary assay is not as readily apparent from its 'CAT profile' as from a single sentence in the  
330 description (Figure 10). In addition, this PubChem record had extensive technical details such  
331 as reagent components, liquid handling volumes and instruments, times of incubation and plate  
332 processing steps, which could be important for identifying matching assays or interpreting the  
333 results. Another example of a poor fit for the CAT, as noted earlier, are *in vivo* assays. These  
334 are largely beyond the scope of this effort, which is currently constrained to terms defined by the  
335 BAO: key parameters such as route of administration, dose, dose units, type of model (e.g.  
336 xenograft, disease) are not well represented. These and other limitations will be addressed in  
337 the future by adding or extending the underlying ontologies.

338 Finally, as noted earlier, we designed the CAT to be a 'one-size-fits-most' template. A summary  
339 of assignments for the complete set of assays annotated in the course of developing the CAT  
340 shows we have achieved this (Table 1). One consequence of this 'one-size-fits-most' strategy  
341 is that certain attributes (such as those highlighted in green or red in Figures 8 and 9) have  
342 been omitted. Depending on one's perspective, these types of data (such as positive and  
343 negative controls, data processing/normalization steps, relevant disease indication, and specific  
344 protocol details such as pre-incubation of compounds with the target, time or temperature of an  
345 assay) could be viewed as essential. We decided to exclude this type of information from the  
346 CAT because of irregularity of appearance in bioassay descriptions, the lack of coverage by the  
347 BAO, or incompatibility with the current data model. Expanding into this area is an opportunity  
348 for future development, and it should be noted that the CAT may be used as a starting point for  
349 templates that provide a set of assignment options that are customized for subcategories of  
350 assays, or even specific projects. We believe the next immediate step should be to apply our  
351 CAT to a large (>10,000) set of assays, both to facilitate new meta-analyses and to identify  
352 potential gaps in annotation revealed by such studies.

## 353 PubChem

354 Possibly the most voluminous source of openly accessible bioassay data can be found on  
355 PubChem, which hosts more than 1.1 million assay records at the time of publication, and is  
356 growing rapidly. These are individually associated with the chemical structures of the  
357 compounds for which the measurements were made. Each of the assays is decorated with  
358 several descriptive fields that are essentially plain text, and which are populated by contributors  
359 during the upload process, or in some cases by an import script transferring data from other  
360 sources. While many of the entries contain a significant amount of detail, the phrasing style and  
361 level of detail varies considerably, often erring on the side of too little or too much information  
362 about the assay protocol.

363 Nonetheless, the PubChem assay collection represents one of the best and most convenient  
364 sources of data for annotation purposes, and for this reason we have added a feature to the  
365 BioAssay Template editor that explicitly searches for PubChem records, as shown in Figure 11.

366 The dialog box allows the user to type in a PubChem Assay ID number, or to hit the button  
367 labelled *Random*, which picks an arbitrary assay from the entire collection, and fills in the  
368 corresponding text and URI of origin. While a large proportion of assays loaded into PubChem  
369 contain only sparse tags about the data source, or the abstract of the corresponding publication,  
370 there are a significant number of records that contain lengthy descriptions of the assay. The  
371 dialog box provides an opportunity for the user to tidy up the text (e.g. removing irrelevant  
372 content) prior to importing it into the schema. The content is then added to the list of assays  
373 being annotated within the schema model, whereby the origin is recorded as a link to the assay,  
374 and the text is associated using the *hasParagraph* predicate. Once the text is augmented with  
375 annotations using the current template, it becomes a useful entry for training data. This is one of  
376 our main strategies for generating a corpus of data for machine-learning purposes, which will  
377 ultimately find its way into a user friendly ELN for bioassay annotation.

## 378 Analysis

379 Because the data model we describe is based on semantic web triples, and the file format that  
380 is used by the BioAssay Schema Editor is made up of triples (in Turtle format), it means that any  
381 templates and assay annotations can be loaded directly into a triple store database, and queried  
382 using SPARQL queries. Content can be hosted on private servers for local use, or it can be  
383 exposed to the greater web of connected data. The supplementary information (Section 1)  
384 describes a configuration script for the open source Apache Fuseki Jena server which can be  
385 used to load the BioAssay Ontology, its related ontologies, and some number of files saved with  
386 the BioAssay Schema Editor, which can then be served up as read-only content.

387 Once the content is available via a SPARQL endpoint, there are a number of boilerplate queries  
388 that can be used to extract summary and specific information. Fetching a list of all bioassay  
389 templates can be accomplished using the following query:

```
390 PREFIX bat: <http://www.bioassayontology.org/bat#>  
391 PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>  
392 SELECT ?template ?label ?descr WHERE  
393 {  
394     ?template a bat:BioAssayTemplate ; rdfs:label ?label .  
395     OPTIONAL {?template bat:hasDescription ?descr .}  
396 }  
397
```

398 The above query identifies any resource that is tagged as having the *BioAssayTemplate* type.  
399 Obtaining information about the assignments that are associated with a template can be done  
400 by looking for resources of type *Group* that are associated with it. Obtaining a summary list of  
401 assignments that are attached to the top level (i.e. not within a subgroup) can be accomplished  
402 with a query similar to the following (using the same prefixes as above) which explicitly  
403 references the common assay template:

```

404 SELECT ?assn ?label ?descr ?property ?numValues
405 {
406     <http://www.bioassayontology.org/bas#CommonAssayTemplate>
407         bat:hasAssignment ?assn .
408     ?assn a bat:Assignment ;
409         rdfs:label ?label ;
410         bat:hasProperty ?property .
411     OPTIONAL {?assn bat:hasDescription ?descr .}
412     {
413         SELECT ?assn (COUNT(?value) as ?numValues) WHERE
414         {
415             ?assn bat:hasValue ?value .
416         }
417         GROUP BY ?assn
418     }
419 }
420 ORDER BY ?label
421

```

422 Similarly, assignments with one level of nesting can be obtained with a slightly longer query,  
 423 which explicitly inserts a subgroup in between the template and assignment:

```

424 SELECT ?group ?glabel ?assn ?label ?descr ?property ?numValues
425 {
426     <http://www.bioassayontology.org/bas#CommonAssayTemplate>
427         bat:hasGroup ?group .
428     ?group a bat:Group ;
429         rdfs:label ?glabel ;
430         bat:hasAssignment ?assn .
431     ?assn a bat:Assignment ;
432         rdfs:label ?label ;
433         bat:hasProperty ?property .
434     {
435         SELECT ?assn (COUNT(?value) as ?numValues) WHERE
436         {
437             ?assn bat:hasValue ?value .
438         }
439         GROUP BY ?assn
440     }
441 }
442 ORDER BY ?glabel ?label
443

```

444 To query for information about the prescribed values for assignment (in this case the bioassay  
 445 assignment from the common assay template), the following query can be used:

```

446     SELECT ?property ?value ?label
447     {
448         <http://www.bioassayontology.org/bas#Bioassay>
449         bat:hasProperty ?property ;
450         bat:hasValue
451         [
452             bat:mapsTo ?value ;
453             rdfs:label ?label
454         ] .
455     }
456

```

457 The query specifically pulls out the *property* field, which is typically a link into the BAO property  
 458 terms, and the *value* field, which is typically a link into the BAO classes. Pursuing either of these  
 459 resources provides a wealth of implicit information, partly from the hierarchical nature of the  
 460 BAO terms, and the unlimited opportunities for these terms to be linked to other semantic  
 461 resources.

462 To obtain a list of assays that have been annotated using one of the templates, the following  
 463 query can be used:

```

464     SELECT ?assay ?label ?descr ?template WHERE
465     {
466         ?assay a bat:BioAssayDescription ;
467         rdfs:label ?label ;
468         bat:usesTemplate ?template .
469         OPTIONAL {?assay bat:hasDescription ?descr .}
470     }
471

```

472 Obtaining all of the annotations for such an assay can be done with:

```

473     SELECT ?assn ?label ?property ?value ?literal ?group WHERE
474     {
475         <http://www.bioassayontology.org/bas#ExampleAssay>
476         bat:hasAnnotation ?annot .
477
478         ?annot bat:isAssignment ?assn ;
479         rdfs:label ?label ;
480         bat:hasProperty ?property .
481         OPTIONAL {?annot bat:hasValue ?value}
482         OPTIONAL {?annot bat:hasLiteral ?literal}
483         ?group a bat:Group ; bat:hasAssignment ?assn .
484     }
485

```

486 Because annotations are directly attached to an assay description, hierarchical information  
 487 about the nature of the assignment can be obtained by further investigating the template  
 488 definition of the assignment (*?assn*) or either of the linked BAO terms (*?property* and *?value*).

## 489 Conclusion

490 We have developed a data model and interactive tool that can be used to narrow the degrees of  
 491 freedom from the BioAssay Ontology (BAO) and its linked dependencies. This has been done in



492 order to facilitate content creation activities, so that semantic annotation of assay protocols can  
493 be carried out by a domain expert with no corresponding expertise with the underlying ontology.  
494 We have provided a proof of concept tool that creates a user interface based on the template  
495 data model, and made this available to the community as open source.

496 The data model that we have created follows a simplistic pattern, where elementary facts can  
497 be asserted. By leveraging the implied value of the underlying ontology, a small collection of a  
498 dozen or so such annotations provides a significant amount of machine-readable context about  
499 the assay. While insufficient to completely define an assay protocol experiment, this stands in  
500 contrast to the standard practice of providing essentially zero machine-readable information (i.e.  
501 plain English text with quasi-standardized jargon).

502 We have made available the *common assay template* (CAT) which was designed by biologists  
503 with the objective of leveraging the BAO to provide the largest amount of useful, relevant,  
504 machine-readable information with the fewest number of additional data points needing to be  
505 captured by the originating scientist. The CAT is expected to be useful for a wide variety of  
506 sorting, filtering, and data aggregating tasks that drug discovery scientists need to be able to  
507 carry out on a large scale, but currently cannot due to the absence of machine-readable  
508 annotations.

509 The CAT prioritizes 16 assignments that biologists consider most central to describing their  
510 assays and reporting assay results. Annotations for these assignments will enable biologists to  
511 ask complex queries. For example, one could ask if there are systematic differences in cell-  
512 based versus biochemical-based assays for a certain target class, such as kinases. One could  
513 determine if a certain assay set-up, such as 96-well plates using a spectrophotometer were  
514 likely to have a higher hit rate. Similarly, one could identify if a certain compound or class of  
515 compounds is active in multiple assays, and if those assays assess similar biological processes  
516 or if the activity is likely to be an artifact.

517 By focusing on 16 assignments out of more than a hundred options available in the BAO, the  
518 CAT is meant to impose a minimal burden for annotating scientists. Our goal is to make  
519 annotating assays simple and easy so that the practice may be generally adopted. Templates  
520 are malleable and scientists can easily include other assignments.

521 One critical type of information that is not included in the current framework is protocol steps,  
522 which would be essential for directly comparing two assays. In the future, it would be useful if  
523 this information were machine-readable. However, semantic technology using a simplistic data  
524 model like the BAT cannot capture sequences of information. Capturing procedural or protocol  
525 steps would require the development of a more complex data model. Under the current system,  
526 we imagine that queries using annotations from the CAT will allow scientists to hone in on  
527 similar assays, but for the moment, experts will still need to read the full assay descriptions to  
528 make decisions about combining different assays' data sets.

529 We have carried out this work in the context of a much larger scope, which is to provide  
530 scientists with tools to easily annotate bioassays and other related experiments in a way that is  
531 complete and machine-readable. Given that the standard industry practice does not involve  
532 adding any machine readable data to assay protocols, and that there are currently no widely  
533 available tools to do so with a user experience that is sufficiently painless for mass adoption, we  
534 have taken an incremental approach. This additional work has been done in order that we can  
535 continue with our previous work that was focused on using machine learning techniques to  
536 accelerate manual assignment of assays.<sup>15</sup> Our immediate follow-up goals are to make use of  
537 the CAT to gather a large corpus of training data, both from active users of CDD Vault, and from  
538 existing repositories such as PubChem. This training data will be used to ensure that our

539 enterprise ELN tools will be supported by machine learning technology as soon as they are  
540 unveiled.

541 We are also pursuing options for extending the BioAssay Template (BAT) data model so that it  
542 is capable of capturing more sophisticated information about assays, e.g. linking to other  
543 ontologies to cover more types of assays; adding terminology for capturing quantities; addition  
544 of indefinite numbers of preparation steps; dependent assignment types, etc. One critical step  
545 when we enable connecting with other ontologies will be the ability to link the 'Target' to a  
546 unique identifier such as geneid or UniProtID. Each unique target identifier can be associated  
547 with a rich array of corresponding GO terms, of which a subset are mapped into the default  
548 selection of BAO classes. This will enable comparison of assays based on specific targets and  
549 related biological processes or molecular functions. While our first objective is *horizontal*  
550 scaling, i.e. ensuring that all assay protocols have semantic annotations that make a large  
551 portion of the content machine-readable, pursuing *vertical* scaling is also of great interest, i.e.  
552 making it possible for the semantic annotations to replace the need for use of English text.<sup>29</sup>  
553 This brings about some exciting possibilities beyond just improvement of searching and  
554 matching, such as uploading protocols to robotic assay machinery, or making the publication  
555 process multi-lingual, thus alleviating a considerable burden to non-native English speakers.  
556 Pursuing this goal will require significant additions to the BAO itself, as well as making  
557 increased use of borrowed terms from other ontologies.

558 The technology that we have described in this article has been created for the purpose of  
559 improving the electronic lab notebook (ELN) technology that is offered by Collaborative Drug  
560 Discovery, Inc. (CDD), and we have begun work on a web-based interface for using templates  
561 such as the CAT for annotating assay protocols.<sup>30</sup> We have disclosed all of the underlying  
562 methods, data and open source code because we welcome participation by anyone and  
563 everyone. While CDD is a privately held for-profit company, it is our firm belief that improvement  
564 to this particular aspect of scientific research is a positive sum game, and we have more to gain  
565 by sharing than by keeping our technology entirely proprietary.

## 566 **Supporting Materials**

567 The BioAssay Schema Editor is publicly available from GitHub ([https://github.com/cdd/bioassay-](https://github.com/cdd/bioassay-template)  
568 [template](https://github.com/cdd/bioassay-template)). The source code for the application is available under the terms of the Gnu Public  
569 License (GPL) v2, which requires that derived works must also be similarly open. The  
570 underlying semantic data model for the template and assay annotation, as well as the common  
571 assay template (CAT), are public domain: they are not copyrighted, and no restrictions are  
572 placed on their use. The BioAssay Ontology (BAO) is available from the corresponding site  
573 (<http://bioassayontology.org/bioassayontology>) under the Creative Commons Attribution License  
574 v3.

575

576 **Tables****Table 1. Representation of Common Assay Template in Sample Assay Set**

CAT Assignment	Test Assays (of 43) With at Least 1 Value	# of Unique Values Annotated
bioassay type	43 (100%)	24 of 88
assay format	43 (100%)	6 of 19
assay design method	43 (100%)	20 of 76
assay cell line	24 (55.8%)	15 of 95
organism	41 (95.3%)	11 of 65
biological process	40 (93.0%)	28 of 54
target	32 (74.4%)	13 of 38
assay mode of action	43 (100%)	8 of 13
result	41 (100%)	16 of 94
result unit of measurement	32 (74.4%)	6 of 56
assay screening campaign stage	40 (93.0%)	8 of 23
assay footprint	36 (83.7%)	5 of 20
assay kit	9 (20.9%)	5 of 93
physical detection method	42 (97.7%)	11 of 51
detection instrument	26 (60.5%)	9 of 97
perturbagen type	20 (46.5%)	3 of 9

577

578 **Figure Captions**

579 **Figure 1:** A selection of the BioAssay Ontology hierarchy, visualized using BioPortal  
 580 (<http://bioportal.bioontology.org>): (a) classes and (b) properties.

581 **Figure 2:** An overview of the *common assay template* (CAT) at the time of publication.

582 **Figure 3:** BioAssay Template data model, which is used to describe a template.

583 **Figure 4:** Data model for annotated assays, which is used to apply a template to a specific  
 584 assay.

585 **Figure 5:** A snapshot of the BioAssay Schema Editor. On the left hand side the current template  
 586 is shown at the top (with its hierarchy of groups and assignments), and any assays currently in  
 587 progress shown underneath. The panel on the right shows the details for an assignment - *assay*  
 588 *format* - and the prescribed values that are associated with it.

589 **Figure 6:** A snapshot of the two main tabs used for locating a value in the BioAssay Ontology.  
 590 The left hand side (a) shows the list view, which is flat, while the right hand side (b) shows the  
 591 values in context of the actual hierarchy of the underlying ontology.

592 **Figure 7:** A snapshot of the annotation interface that is available within the template editor (a).  
593 The current template can be applied to specific assays within the same overall user interface,  
594 which is a convenient way to evaluate its suitability. Selecting any of the assignments brings up  
595 a dialog box presenting all of the prescribed values (b).

596 **Figure 8. Example of PubChem Assay text ideally suited for annotation with the CAT.**  
597 **Left:** Text from description in PubChem Assay ID 427: yellow = information captured in CAT,  
598 green = information not captured but possible for a future version (e.g., controls, data  
599 processing), red= information beyond the scope of BAO (technical details) **Right:** CAT  
600 assignments in BioAssay Schema Editor.

601 **Figure 9. Example of PubChem Assay text ideally suited for annotation with the CAT.**  
602 **Left:** Text from description in PubChem Assay ID 440: yellow = information captured in CAT,  
603 pink = information added as 'literal' values (i.e., too specific to exist as a BAO entry, but deemed  
604 valuable), green = information not captured but possible for a future version (e.g., controls, data  
605 processing), red= information beyond the scope of BAO (technical details). **Right:** CAT  
606 assignments in BioAssay Schema Editor. Annotations added as 'literal' values are highlighted  
607 yellow and contained in single quotes. Note that multiple values for a single CAT assignment  
608 can be annotated (*target biological process, assay mode of action, assay screening campaign*  
609 *stage, perturbagen type*).

610 **Figure 10. Example of an assay partially suited for annotation with the CAT.** **Left:** Text  
611 from description in PubChem Assay ID 488847: yellow = information captured in CAT, pink=  
612 information added as 'literal' values (i.e., too specific to exist as a BAO entry, but deemed  
613 valuable), green = information not captured but possible for a future version (e.g., controls,  
614 labels of target and ligand, assay quality data (Z')), red= information beyond the scope of BAO  
615 (technical details). **Right:** CAT values assigned in the BioAssay Schema Editor capture key  
616 parameters of the assay yet do not capture the complexity of the assay articulated in the single  
617 sentence (arrow): "a flow cytometry protein interaction assay to screen for compounds that  
618 compete with RNA binding to GRK2".

619 **Figure 11:** Dialog box for random lookup of assays from PubChem.

620

## 621 References

1. A.M. Clark, A.J. Williams, S. Ekins: Machines first, humans second: on the importance of algorithmic interpretation of open chemistry data, *Journal of Cheminformatics*, 7:9 (2015) DOI 10.1186/s13321-015-0057-7
2. A. Hersey, S. Senger, J.P. Overington: Open data for drug discovery: learning from the biological community. *Future Medicinal Chemistry*, 4, 1865-1867 (2012) DOI 10.4155/fmc.12.159
3. G.F. Ecker, B. Williams-Jones: Editorial: Open Innovation in Drug Discovery. *Molecular Informatics*, 31, 519-520 (2012) DOI 10.1002/minf.201280004
4. A.J. Williams, J. Wilbanks, S. Ekins S: Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models. *PLoS Computational Biology*, 8:e1002706 (2012) DOI 10.1371/journal.pcbi.1002706
5. K.Y. Helal, M. Maciejewski, E. Gregori-Puigjane, M. Glick, A.M. Wassermann: Public Domain HTS Fingerprints: Design and Evaluation of Compound Bioactivity Profiles from

- PubChem's Bioassay Repository. *Journal of Chemical Information and Modeling*, just accepted (2016) DOI 10.1021/acs.jcim.5b00498
6. E. Bolton: Reporting biological assay screening results for maximum impact, *Drug Discovery Today: Technologies*, **14**, 31-36 (2015) DOI 10.1016/j.ddtec.2015.03.004
  7. It should be noted that the majority of the first million PubChem assays do not contain detailed experimental assay descriptions. Contributors such as the Broad Institute and organizations affiliated with the Molecular Libraries Screening Center can be selected by browsing the sources: <http://pubchem.ncbi.nlm.nih.gov/sources/sources.cgi>
  8. A. Gaulton, L.J. Bellis, A.P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani, J.P. Overington: ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Research*, D1100-D1107 (2012) DOI 10.1093/nar/gkr777
  9. The materials for the BioAssay Ontology can be found at <http://bioassayontology.org>
  10. S. Abeyruwan, U.D. Vempati, H. Küçük, U. Visser, A. Koletti, A. Mir, K. Sakurai, C. Chung, J. Bittker, P. Clemons, S. Brudz, A. Siripala, A. Morales, M. Romacker, D. Twomey, S. Bureeva, V. Lemmon, S.C. Schürer: Evolving BioAssay Ontology (BAO): Modularization, Integration and Applications, *Journal of Biomedical Semantics*, **5**, 1:S5 (2014) DOI 10.1186/2041-1480-5-S1-S5
  11. U.D. Vempati, M.J. Przydzial, C. Chung, S. Abeyruwan, A. Mir, K. Sakurai, U. Visser, V.P. Lemmon, S.C. Schürer: Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO). *PLoS One*, e49198 (2012) DOI: 10.1371/journal.pone.0049198
  12. S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. Wang, B. Yu, J. Zhang, S.H. Bryant: PubChem Substance and Compound databases. *Nucleic Acids Research*, D1202-13 (2016) DOI: 10.1093/nar/gkv951
  13. E.L. Willighagen, A. Waagmeester, O. Spjuth, P. Ansell, A.J. Williams, V. Tkachenko, J. Hastings, B. Chen, D.J. Wild: The ChEMBL database as linked open data. *Journal of Cheminformatics*, **5**:23 (2013) DOI: 10.1186/1758-2946-5-23
  14. A. de Souza, J.A. Bittker, D.L. Lahr, S. Brudz, S. Chatwin, T.I. Oprea, A. Waller, J.J. Yang, N. Southall, R. Guha, S.C. Schürer, U.D. Vempati, M.R. Southern, E.S. Dawson, P.A. Clemons, T.D.Y. Chung: An Overview of the Challenges in Designing, Integrating, and Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and Disciplines. *Journal of Biomedical Screening*, **19**, 614-627 (2014) DOI: 10.1177/1087057113517139
  15. A.J. Williams, L. Harland, P. Groth, S. Pettifer, C. Chichester, E.L. Willighagen, C.T. Evelo, N. Blomberg, G. Ecker, C. Goble, B. Mons: Open PHACTS: semantic interoperability for drug discovery. *Drug Discovery Today*, **17**, 1188-1198 (2012) DOI: 10.1016/j.drudis.2012.05.016
  16. The Gene Ontology Consortium. Gene Ontology Consortium: going forward. (2015) *Nucl Acids Res* **43** Database issue D1049–D1056 [Online at Nucleic Acids Research](#)
  17. It can also be browsed and edited using software such as Protégé, which can be found at <http://protege.stanford.edu>
  18. A.M. Clark, B.A. Bunin, N.K. Litterman, S.C. Schürer, U. Visser: Fast and accurate semantic annotation of bioassays exploiting a hybrid of machine learning and user confirmation. *PeerJ*, **2**:e524 (2014) DOI 10.7717/peerj.524
  19. A. de Souza, J.A. Bittker, D.L. Lahr, S. Brudz, S. Chatwin, T.I. Oprea, A. Waller, J.J. Yang, N. Southall, R. Guha, S.C. Schürer, U.D. Vempati, M.R. Southern, E.S. Dawson, P.A. Clemons, T.D.Y. Chung: An Overview of the Challenges in Designing, Integrating, and




- 
- Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and Disciplines. *Journal of Biomedical Screening*, **19**, 614-627 (2014) DOI: 10.1177/1087057113517139
20. Y. Wang Y, T. Suzek, J. Zhang, J. Wang, S. He, T. Cheng, B.A. Shoemaker, A. Gindulyte, S.H. Bryant: PubChem BioAssay: 2014 update. *Nucleic Acids Research*, D1075-82 (2014) DOI 10.1093/nar/gkt978
21. S.C. Schürer, U. Vempati, R. Smith, M. Southern, V. Lemmon: BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets. *Journal of Biomolecular Screening*, 16:415–426 (2011) DOI 10.1177/1087057111400191
22. See W3C Resource Description Framework: <http://www.w3.org/RDF>
23. See W3C RDF Turtle: <http://www.w3.org/TR/turtle>
24. Gnu Public License 2.0: <http://www.gnu.org/licenses/gpl-2.0.en.html>: the license allows anyone to use the source code for any purpose, on the condition that products making use of it must be made available under a license that is at least as open. Copyright for the project is held by Collaborative Drug Discovery, Inc.
25. See Apache Jena project: <http://jena.apache.org>
26. Downloadable OWL files for the BioAssay Ontology: <http://bioassayontology.org/bioassayontology>
27. Y. Wang Y, T. Suzek, J. Zhang, J. Wang, S. He, T. Cheng, B.A. Shoemaker, A. Gindulyte, S.H. Bryant: PubChem BioAssay: 2014 update. *Nucleic Acids Research*, D1075-82 (2014) DOI 10.1093/nar/gkt978
28. S.C. Schurer, U. Vempati, R. Smith, M. Southern, V. Lemmon: BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets. *Journal of Biomolecular Screening*, 16:415–426 (2011) DOI 10.1177/1087057111400191
29. L.N. Soldatova, D. Nadis, R.D. King, P.S. Basu, E. Haddi, V. Baumié, N.J. Saunders, W. Marwan, B.B. Rudkin: EXACT2: the semantics of biomedical protocols. *BMC Bioinformatics*, **15**, S5 (2014) DOI: 10.1186/1471-2105-15-S14-S5
30. A preliminary version of the web interface can be found at <http://bioassayexpress.com>. At the time of writing this service is in an early pre-alpha phase, but will be updated as the project progresses.

1

A selection of the BioAssay Ontology hierarchy, visualized using BioPortal (<http://bioportal.bioontology.org>): (a) classes and (b) properties.

**Figure 1:** A selection of the BioAssay Ontology hierarchy, visualized using BioPortal (<http://bioportal.bioontology.org>): (a) classes and (b) properties.

(a) 

BioPortal

BioAssay Ontology

Summary Classes Properties Notes Mappings Widgets


Jump To:

- assay bioassay component
  - assay kit
  - bioassay
  - bioassay specification
  - bioassay type
    - ADMET**
    - binding type
    - functional
    - physicochemical
  - experimental specification
  - measure group
  - measure group specification
- assay biology component
- assay endpoint component
- assay format component
- assay method component
- assay screened entity component
- organization
- people
- quality
- role

Details Visualization Notes (0) Class Mappings (0)

Preferred Name	ADMET
Definitions	ADMET stands for absorption, distribution, metabolism, excretion and toxicity. Admet assays are performed for verifying the bio-availability, toxicity, metabolic stability, and drug-drug interaction potential of drugs: They quantify absorption of drugs in the intestine which is dependent on their solubility; distribution which ascertains their binding to plasma proteins, central nervous system penetration; metabolism where the in vivo clearance is monitored; and finally, toxicity in terms of inhibition of liver cytochrome p450 enzymes or hERG which could cause drug-drug interactions and cardiac arrhythmias, respectively.
ID	<a href="http://www.bioassayontology.org/bao#BAO_0000009">http://www.bioassayontology.org/bao#BAO_0000009</a>
definition	ADMET stands for absorption, distribution, metabolism, excretion and toxicity. Admet assays are performed for verifying the bio-availability, toxicity, metabolic stability, and drug-drug interaction potential of drugs: They quantify absorption of drugs in the intestine which is dependent on their solubility; distribution which ascertains their binding to plasma proteins, central nervous system penetration; metabolism where the in vivo clearance is monitored; and finally, toxicity in terms of inhibition of liver cytochrome p450 enzymes or hERG which could cause drug-drug interactions and cardiac arrhythmias, respectively.
label	ADMET
prefLabel	ADMET
subClassOf	bioassay.type

The National Center for Biomedical Ontology is one of the National Centers for Biomedical Computing supported by the NHGRI, the NHLBI, and the NIH Common Fund under grant U54-HG004028.  
Copyright © 2005-2016, The Board of Trustees of Leland Stanford Junior University. All rights reserved.  
NCBO Website Release Notes Terms of Use Privacy Policy How to Cite

(b) 

BioAssay Ontology

Summary Classes Properties Notes

- alternative term
- alternative\_term
- axiom\_lost\_from\_external\_ontology
- based\_on\_normalization
- bearer of
- bioportal\_provenance
- connected to
- contains process
- created\_by
- creation\_date
- database\_cross\_reference
- date
- definition
- definition source
- definition\_citation
- definition\_editor
- definition\_note
- derives from
- derives into
- detects phenotype
- dubious\_for\_taxon
- editor note
- editor preferred term
- encodes
- expand assertion to
- external\_definition
- fma\_set\_term
- has activity threshold value
- has antibody source
- has assay control
- has assay footprint
- has assay kit**
- has assay kit component
- has assay medium
- has assay pH value

**Figure 2** (on next page)

An overview of the *common assay template* (CAT)

**Figure 2:** An overview of the *common assay template* (CAT) at the time of publication.

**bioassay type** → ADMET  
 apoptosis assay  
 beta galactosidase enzyme activity assay  
 beta galactosidase reporter gene assay  
 beta lactamase reporter gene assay  
 binding assay  
 bioavailability assay  
 calcium redistribution assay  
 cAMP redistribution assay  
 (+ 79 more)

**assay format** → biochemical format  
 cell based format  
 cell membrane format  
 cell-free format  
 cytosol format  
 microsome format  
 mitochondrion format  
 nuclear extract format  
 nucleic acid format  
 (+ 10 more)

**assay design method** → antigen down assay  
 ATP quantitation  
 ATP quantitation using luciferase  
 beta galactosidase induction  
 beta lactamase induction  
 binding assessment method  
 caspase activity determination  
 cell cycle progression assessment method  
 cell movement measurement method  
 (+ 67 more)

**assay cell line** → 293 cell  
 293T/17 cell  
 A2780  
 A549 cell  
 ACHN cell  
 AML12 cell  
 BA/F3 cell  
 BJ  
 BSC-1  
 (+ 86 more)

**organism** → Arabidopsis thaliana  
 bacterium  
 Bluetongue virus 10  
 Bos taurus  
 Caenorhabditis elegans  
 Candida albicans  
 Canis lupus familiaris  
 cellular organisms  
 Chlorocebus aethiops  
 (+ 56 more)

**biological process** → absence  
 alternative mRNA splicing, via spliceosome  
 ambiguous  
 apoptotic process  
 autophagy  
 biofilm formation  
 calcium-mediated signaling using intracellular calcium source\_bao  
 cAMP-mediated signaling\_BAO  
 cell cycle  
 (+ 45 more)

**target** → adhesion  
 carbohydrate  
 chaperone  
 cytosolic protein  
 enzyme  
 enzyme regulator  
 G protein  
 G protein coupled receptor  
 generic hydrolase  
 (+ 29 more)

**assay mode of action** → activation  
 agonism  
 antagonism  
 competitive binding  
 inhibition  
 irreversible binding  
 ligand binding mode of action  
 ligand function mode of action  
 modulation  
 (+ 4 more)

**result** → 50 percent activation  
 50 percent inhibition  
 80 percent inhibition  
 90 percent inhibition  
 AC10 absolute  
 AC1000 absolute  
 AC26 absolute  
 AC35 absolute  
 AC40 absolute  
 (+ 85 more)

**result unit of measurement** → angstrom  
 catalytic (activity) concentration unit  
 cell concentration unit  
 cells per milliliter  
 centimeter  
 century  
 concentration unit  
 concentration unit  
 counts per second  
 (+ 47 more)

**assay screening campaign stage** → alternate assay conditions  
 alternate assay format  
 alternate assay type  
 alternate cell line assay  
 alternate confirmatory assay  
 alternate organism assay  
 alternate target assay  
 compound aggregation assay  
 compound fluorescence assay  
 (+ 14 more)

**assay footprint** → 1536 well plate  
 24 well plate  
 384 well plate  
 96 well plate  
 array  
 cuvette  
 gene array  
 HYPER flask  
 microplate  
 (+ 11 more)

**assay kit** → Adapta Universal Kinase Assay Kit  
 ADP Glo Kinase Assay  
 ADP Hunter Plus  
 AlphaScreen cAMP assay kit  
 AlphaScreen cGMP Detection  
 AlphaScreen GST detection kit  
 AlphaScreen IgG detection kit  
 AlphaScreen Phosphotyrosine Assay Kit  
 Alphascreen second messenger IP1 detection kit  
 (+ 84 more)

**physical detection method** → absorbance  
 alphascreen  
 atomic absorption spectrophotometry  
 bio layer interferometry  
 bioluminescence  
 brightfield microscopy  
 carbon nanotube based sensor  
 chemiluminescence  
 circular dichroism  
 (+ 42 more)

**detection instrument** → 3i Marianas  
 8453 UV-Visible Spectrophotometer  
 Acumen  
 AlphaQuest reader  
 AMINCO-Bowman Series 2 Luminescence Spectrometer  
 Analyst HT  
 API 4000 LC/MS/MS System  
 Applied biosystems 8200  
 ArrayScan 3.1 HCS Reader  
 (+ 88 more)


**perturbagen type** → compound library  
 DIVERSet  
 LOPAC 1280  
 miRNA library  
 MLSMR library  
 NINDS library  
 shRNA library  
 siRNA library  
 The NatProd Collection

**Figure 3** (on next page)

BioAssay Template data model

**Figure 3:** BioAssay Template data model, which is used to describe a template.





**Figure 4**(on next page)

Data model for annotated assays

**Figure 4:** Data model for annotated assays, which is used to apply a template to a specific assay.

Assay

bat:hasAnnotation

Annotation


```
rdf:type bat:BioAssayDescription
rdfs:label ^^xsd:string
bat:hasDescription ^^xsd:string
bat:usesTemplate reference
bat:hasParagraph ^^xsd:string
bat:hasOrigin reference
```

```
isAssignment reference
rdfs:label ^^xsd:string
bat:hasDescription ^^xsd:string
bat:hasProperty reference
bat:hasValue reference
bat:hasLiteral literal
```

## 5

## A snapshot of the BioAssay Schema Editor


**Figure 5:** A snapshot of the BioAssay Schema Editor. On the left hand side the current template is shown at the top (with its hierarchy of groups and assignments), and any assays currently in progress shown underneath. The panel on the right shows the details for an assignment - *assay format* - and the prescribed values that are associated with it.



## 6

A snapshot of the two main tabs used for locating a value in the BioAssay Ontology

**Figure 6:** A snapshot of the two main tabs used for locating a value in the BioAssay Ontology. The left hand side (a) shows the list view, which is flat, while the right hand side (b) shows the values in context of the actual hierarchy of the underlying ontology.






7

A snapshot of the annotation interface that is available within the template editor

**Figure 7:** A snapshot of the annotation interface that is available within the template editor

(a). The current template can be applied to specific assays within the same overall user interface, which is a convenient way to evaluate its suitability. Selecting any of the assignments brings up a dialog box presenting all of the prescribed values (b).



**Figure 8**(on next page)

First example of PubChem Assay text ideally suited for annotation with the CAT

**Figure 8. Example of PubChem Assay text ideally suited for annotation with the CAT. Left:** Text from description in PubChem Assay ID 427: yellow = information captured in CAT, green = information not captured but possible for a future version (e.g., controls, data processing), red= information beyond the scope of BAO (technical details) **Right:** CAT assignments in BioAssay Schema Editor.

## PubChem Assay (ID 427)

Origin: <http://pubchem.ncbi.nlm.nih.gov/bioassay/427>

bioassay type  $\xrightarrow{\text{has bioassay}}$  cell viability assay

assay format  $\xrightarrow{\text{has assay format}}$  cell based format

assay design method  $\xrightarrow{\text{has assay design method}}$  ATP quantitation using luciferase

assay cell line  $\xrightarrow{\text{is cell line of}}$  HEK293

organism  $\xrightarrow{\text{has organism}}$  Homo sapiens

biological process  $\xrightarrow{\text{has biological process}}$  cell death

target  $\xrightarrow{\text{has biological macromolecule}}$  (not assigned)

assay mode of action  $\xrightarrow{\text{has mode of action}}$  modulation

result  $\xrightarrow{\text{has result}}$  AC50

result unit of measurement  $\xrightarrow{\text{has unit of measurement}}$  (not assigned)

assay screening campaign stage  $\xrightarrow{\text{has assay stage}}$  primary assay

assay footprint  $\xrightarrow{\text{has assay footprint}}$  1536 well plate

assay kit  $\xrightarrow{\text{uses assay kit}}$  CellTiter-Glo Luminescent Cell Viability Assay

physical detection method  $\xrightarrow{\text{has detection method}}$  luminescence method

detection instrument  $\xrightarrow{\text{uses detection instrument}}$  (not assigned)

perturbagen type  $\xrightarrow{\text{has perturbagen}}$  compound library

We have developed a 1536-well cell-based assay for quantitative high throughput screening (qHTS) against a number of cell lines to determine in vitro cytotoxicity of small molecules. This particular assay uses the Hek 293 cell line which is derived from human embryonic kidney cells (transformed with adenovirus). The CellTiter-Glo luminescent cell viability assay (Promega) is a homogeneous method to measure the number of viable cells in culture. The end point readout of this assay is based on quantitation of intracellular ATP, an indicator of metabolic activity, using the luciferase reaction. Luciferase catalyzes the oxidation of beetle Luciferin to oxyluciferin and light in the presence of ATP. The luminescent signal is proportional to amount of ATP present. Using the CellTiter-Glo luminescent cell viability assay, the amount of cellular ATP was measured in the Hek293 cell line with complete culture medium following compound treatment for 40 hours. The assay was performed in opaque white Kalypsys 1536-well plates. In the screen, tamoxifen and doxorubicin were used as positive controls. Library compounds were measured for their ability to cause acute toxicity in the cell line, as reflected by a decrease in intracellular ATP levels, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (100  $\mu\text{M}$  tamoxifen). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

## Key

Annotated with URI

Added as literal

Not annotated: missed opportunity

Requires more advanced template model

**Figure 9** (on next page)

Second example of PubChem Assay text ideally suited for annotation with the CAT

**Figure 9. Example of PubChem Assay text ideally suited for annotation with the CAT.** **Left:** Text from description in PubChem Assay ID 440: yellow = information captured in CAT, pink = information added as 'literal' values (i.e., too specific to exist as a BAO entry, but deemed valuable), green = information not captured but possible for a future version (e.g., controls, data processing), red= information beyond the scope of BAO (technical details). **Right:** CAT assignments in BioAssay Schema Editor. Annotations added as 'literal' values are highlighted yellow and contained in single quotes. Note that multiple values for a single CAT assignment can be annotated (*target biological process, assay mode of action, assay screening campaign stage, perturbagen type*).

The assay reported here uses flow cytometry to measure test compound competition with a high-affinity fluorescent ligand for binding to human FPR. The assay was performed in a "duplex" format in which U937 cells expressing FPR were tested together with a Rat Basophilic Leukemia (RBL) cell line that expressed the related receptor, FPRL1. The FPR-expressing cells were stained with a red-fluorescent dye, FURA-red, to allow them to be distinguished from the FPRL1-expressing cells during flow cytometric analysis. A fluorescein label was conjugated to the lysine residue of the peptide, WKYVMv (WPep), to produce a fluorescent ligand (WPep-FITC) that bound FPR and FPRL-1 with high affinity. Dissociation constants (Kd) for binding of WPep-FITC to FPR and FPRL1 were determined to be 10 nM and 8 nM, respectively. WPep-FITC was used as the fluorescent ligand in the duplex FPR-FPRL1 assay to determine compound activity for both receptors. A set of 9,993 compounds, designated the 10K Set Type 1 (10KST1), and a separate set of 16,322 compounds, designated the 17K Set Type 1 (17KST1), was obtained from the Molecular Libraries Small Molecule Repository (MLSMR) maintained by Discovery Partners International in conjunction with the NIH Molecular Libraries Screening Center Network. There was an overlap of 2,595 compounds common to the two sets so that the total number of unique compounds evaluated in these two sets was 23,720. An additional 586 compounds were cherry picked from the remainder of the MLSMR compound collection on the basis of a previously described virtual screening approach for predicting FPR activity.

The primary high throughput screening (HTS) assay was performed in 384 well format. Test compounds were assessed at a single concentration of 6.7 microM for the ability to inhibit fluorescent ligand binding, detected as a decrease in cell fluorescence due to displacement of fluorescent ligand from FPR. The FPRL1 primary HTS assay results obtained in parallel in the same wells have been reported separately (AID 441) and represent counter-screen data with which to determine selectivity and specificity of compounds with FPR binding activity identified in this report. Likewise, FPR binding results reported here represent counter-screen data with which to determine the selectivity and specificity of compounds identified to have FPRL1 binding activity in the FPRL1 primary HTS assay report (AID 441) For assay performance, additions to wells were in sequence as follows: 1) test compounds and control reagents (5 microL/well); 2) a combination of FPR- and FPRL1-expressing cell lines (10<sup>4</sup>/mL each, 5 microL/well); 3) (after 30 min, 4 degrees C incubation) fluorescent peptide (5 microL/well). After an additional 45 min, 4 degrees C incubation, plates were immediately analyzed by flow cytometry. The assay response range was defined by replicate control wells containing unlabeled receptor-blocking peptide (positive control) or buffer (negative control). fMLFF (4Pep) was used as the FPR-blocking peptide, unlabeled WPep as the FPRL1-blocking peptide. The assay was homogeneous in that cells, compounds and fluorescent peptide were added in sequence and the wells subsequently analyzed without intervening wash steps. The HyperCyt high throughput flow cytometry platform was used to sequentially sample cells from wells of 384-well microplates (2 microL/sample) for flow cytometer presentation at a rate of 40 samples/min. The resulting time-resolved data files were analyzed with IDLeQuery software to determine compound activity in each well.

## PubChem Assay (ID 440)

Origin: <http://pubchem.ncbi.nlm.nih.gov/bioassay/440>

bioassay type  $\xrightarrow{\text{has bioassay}}$  protein-small molecule interaction assay  
assay format  $\xrightarrow{\text{has assay format}}$  cell based format  
assay design method  $\xrightarrow{\text{has assay design method}}$  fluorescent ligand binding method  
assay cell line  $\xrightarrow{\text{is cell line of}}$  U-937 cell  
organism  $\xrightarrow{\text{has organism}}$  Homo sapiens  
biological process  $\xrightarrow{\text{has biological process}}$  neutrophil activation  
G-protein coupled receptor signaling pathway  
target  $\xrightarrow{\text{has biological macromolecule}}$  G protein coupled receptor  
"FPR"  
assay mode of action  $\xrightarrow{\text{has mode of action}}$  inhibition  
ligand binding mode of action  
competitive binding  
result  $\xrightarrow{\text{has result}}$  percent inhibition  
result unit of measurement  $\xrightarrow{\text{has unit of measurement}}$  percent  
assay screening campaign stage  $\xrightarrow{\text{has assay stage}}$  primary assay  
counter screening assay  
assay footprint  $\xrightarrow{\text{has assay footprint}}$  384 well plate  
assay kit  $\xrightarrow{\text{uses assay kit}}$  (not assigned)  
physical detection method  $\xrightarrow{\text{has detection method}}$  flow cytometry  
detection instrument  $\xrightarrow{\text{uses detection instrument}}$  HyperCyt High Throughput Flow Cytometry System  
perturbagen type  $\xrightarrow{\text{has perturbagen}}$  MLSMR library  
"17K Set Type 1 (17KST1)"  
"10K Set Type 1 (10KST1)"




**Figure 10**(on next page)

Example of an assay partially suited for annotation with the CAT

**Figure 10. Example of an assay partially suited for annotation with the CAT. Left:**

Text from description in PubChem Assay ID 488847: yellow = information captured in CAT, pink= information added as 'literal' values (i.e., too specific to exist as a BAO entry, but deemed valuable), green = information not captured but possible for a future version (e.g., controls, labels of target and ligand, assay quality data (Z')), red= information beyond the scope of BAO (technical details). **Right:** CAT values assigned in the BioAssay Schema Editor capture key parameters of the assay yet do not capture the complexity of the assay articulated in the single sentence (arrow): "a flow cytometry protein interaction assay to screen for compounds that compete with RNA binding to GRK2".

**Assay Background and Significance:**

A small family of G protein-coupled receptor (GPCR) kinases (GRKs) negatively regulates heterotrimeric G protein signaling by phosphorylating multiple sites in the cytoplasmic loops and tails of activated GPCRs [Krupnick, et al. 1998]. Through this process, cells adapt to persistent stimuli that act at GPCRs and protect themselves from damage incurred by sustained signaling. GRKs can also play maladaptive roles in human disease. GRK2 is overexpressed during heart failure, which not only uncouples cardiac receptors from the central nervous system, but also promotes the release of excessive amounts of catecholamines from the adrenal gland [Vatner, et al 1996]. Inhibition of GRK2 by transgenic peptides prevents cardiac failure in mouse models [Rockman, et al. 1998], suggesting that GRK2 is an excellent target for the treatment of heart disease. However, selective small molecule inhibitors of GRKs have not been reported, perhaps due to high homology among the active sites of GRKs and other AGC kinases. Over the last six years, our lab has made significant progress in understanding the structure and function of GRKs, and we are currently investigating the molecular basis for the selective inhibition of GRK2 by a high affinity RNA aptamer [Tse and Boger, 2005].

Preliminary crystallographic studies of this complex demonstrate that the aptamer binds primarily to the large lobe of the kinase domain, where it blocks the entrance to the nucleotide binding site of the kinase domain. In the HTS assay reported here, an RNA aptamer is used in a displacement assay to identify small molecules that bind to regions on GRK2 outside of its active site that are also critical for activity. This is a robust flow cytometry protein interaction assay to screen for compounds that compete with RNA binding to GRK2. Using activity-based secondary screens, we will confirm which hits derived from HTS campaigns exhibit direct binding to GRK2 and inhibit kinase activity. These compounds will be further characterized to establish membrane permeability, their mode of inhibition, and their selectivity for GRK2. Although all active molecules are of interest, small molecules that do not exhibit competitive inhibition with ATP are of particular importance because they would likely represent novel and selective therapeutic leads for the treatment of heart disease.

GRK2 protein is biotinylated using biotinamido-hexanoic acid N-hydroxysuccinimide ester (Sigma). The RNA aptamer is fluorescently labeled on the 3' end with carboxyfluorescein (synthesized and labeled by IDT). Streptavidin-coated beads (Spherotech) are incubated with biotinylated GRK2 (bGRK2) at a final concentration of 2 nM for 30 minutes. The BioTek Microflow liquid dispenser is used to dispense 4 microL of assay buffer to all but column 1 of a 384-well assay plate. The positive (blocked) control containing 50X unlabeled RNA aptamer in assay buffer is dispensed to column 1 by a Microflow liquid dispenser (Biotek, USA). Compounds (10 microM in-well concentration) are transferred to assay wells via 100 nanoL pipette transfer on the Biomek FX liquid dispenser (Beckman Coulter, USA). A total of 3 microL of bead suspension is dispensed into assay wells using the Nanoquot liquid dispenser (BioTek, USA). Plates are incubated at RT for 30 min. 3 microL FAM-C13.28 aptamer (final concentration 2 nanoM, supplied by the assay provider) is added to assay wells using the Microflow liquid dispenser. The reaction is incubated for one hour at RT. In this flow cytometry-based HTS [Kuckuck, et al. 2001] a CyAn flow cytometer (Dako / Beckman Coulter) interfaced with a HyperCyt (IntelliCyt, USA) auto-sampler is used to measure the median fluorescence intensity associated with bead-bound bGRK2.

**Calculation:**

For plates that passed the Z' test ( $Z' > .30$ ) a compound was considered active if the PERCENT\_RESPONSE > .40. The Z' mean for all the plates was 0.8 with a standard deviation of 0.2.

The 40% cutoff corresponds to about three times the standard deviation of PERCENT\_RESPONSE from 'non-fluorescent' test compounds. Negative PERCENT\_RESPONSE is primarily due to test compounds with innate fluorescence.

PUBCHEM\_ACTIVITY\_SCORE = PERCENT\_RESPONSE

PUBCHEM\_ACTIVITY\_OUTCOME = 2 (or ACTIVE) if PUBCHEM\_ACTIVITY\_SCORE > 40, otherwise the

PUBCHEM\_ACTIVITY\_OUTCOME = 1 (or INACTIVE).

## 11

Dialog box for random lookup of assays from PubChem

**Figure 11:** Dialog box for random lookup of assays from PubChem.

The image shows a software dialog box titled "Lookup PubChem". It contains several input fields and a large text area. The "PubChem AID:" field is empty. Below it is a blue link "Edit to suit, then accept.". The "Name:" field contains the text "SAR analysis counterscreen of small molecule antagonists of the CCR6 receptor using a CXCR5". The "Origin URI:" field contains the URL "http://rdf.ncbi.nlm.nih.gov/pubchem/bioassay/AID540340". The "Paragraph:" field contains three paragraphs of text describing the assay: A. Brief Description of the Assay, B. Materials, and C. uHTS Procedures. At the bottom of the dialog box are three buttons: "Random", "Cancel", and "OK".

Lookup PubChem

PubChem AID:

[Edit to suit, then accept.](#)

Name: SAR analysis counterscreen of small molecule antagonists of the CCR6 receptor using a CXCR5

Origin URI: <http://rdf.ncbi.nlm.nih.gov/pubchem/bioassay/AID540340>

Paragraph:

A. Brief Description of the Assay: The purpose of this assay is to detect antagonists that inhibit the activation of the CXCR5 receptor in the CHO-K1 beta-Arrestin Cell Line in 384-well plate format in secondary screening mode.

B. Materials: PathHunter CHO-K1 CXCR5 b-arrestin cell line (DiscoverRx, Cat# 93-0204C2) F12 nutrient mix HAMs (Invitrogen, Cat# 11765) Fetal Bovine Serum, heat-inactivated (Hyclone, Cat# SH30396) 100X Penicillin/Streptomycin Solution (Invitrogen, Cat# 15140-122) Hygromycin B (Roche, Cat# 10843555001) Geneticin (MPBiomedicals, Cat # 1672548) Trypsin-EDTA 0.25% (Invitrogen, Cat# 25200-056) Cell Dissociation Buffer (Invitrogen, Cat# 13151) DPBS (Hyclone, Cat# 30028.02) T225 TC Flask (Nunc, Cat# 159934) 384-well, white, solid-bottom, TC plate (Greiner) CXCL130 peptide (R&D Systems, Cat# 801-CX) PathHunter Detection Reagents (DiscoverRx, Cat# 93-0001) Galacton Star Emerald 11 Cell Assay Buffer

C. uHTS Procedures: Day 1 Cell Seeding 1) Plate 2500 cells/well in 20 uL of assay media into columns 1-24 of a 384-well assay plate, using Biotek dispenser. 2) Centrifuge plates at 500 rpm for 1 minute on a Vspin centrifuge. Wrap plates with saran wrap. 3) Incubate overnight at 37 degrees, 100% relative humidity, 5% CO2 for 16-18 hours. Day 2 Compound Addition 1) Centrifuge compound plates at 500 rpm for 1 minute on a Vspin centrifuge. 2) Using LabCyte Echo 555, transfer 200 nL of DMSO to positive and negative control wells in columns 1 - 2 and 23-24, respectively. Using a dose response protocol, transfer compounds from 10mM and 0.312 mM Echo qualified plates into assay plate columns 3 - 22. (Final concentrations range 66 uM to 0.128 uM, 10 doses, with 0.66% DMSO.) 3) Immediately following compound/DMSO transfer via the Echo, using the Biotek Dispenser, transfer 10ul/well of Assay media to Col. 1-2 for the positive control wells. 4) Using the Biotek Dispenser, add 10ul/well of 225 nM CXCL13 (FAC = 75 nM) in assay media to Col. 3-24 for the negative control and test compound wells. 5) Centrifuge plates at 1000 rpm for 1 minute on a Vspin centrifuge. 6) Incubate plates at 25 degrees in the dark for 90 minutes. 7) Following 90 minute incubation, deliver 15 uL of Detection Reagent solution to each assay plate (Columns 1 - 24) using a Biotek dispenser. 8) Centrifuge plates at 2000 rpm for 2 minute on a Vspin centrifuge. 9) Incubate plates for 60 minutes at 25 degrees in

Random Cancel OK

**Table 1** (on next page)

Representation of Common Assay Template in Sample Assay Set

Table 1. Representation of Common **Assay T**emplate in Sample Assay Set[b]

**Table 1. Representation of Common Assay Template in Sample Assay Set**

<b>CAT Assignment</b>	<b>Test Assays (of 43) With at Least 1 Value</b>	<b># of Unique Values Annotated</b>
bioassay type	43 (100%)	24 of 88
assay format	43 (100%)	6 of 19
assay design method	43 (100%)	20 of 76
assay cell line	24 (55.8%)	15 of 95
organism	41 (95.3%)	11 of 65
biological process	40 (93.0%)	28 of 54
target	32 (74.4%)	13 of 38
assay mode of action	43 (100%)	8 of 13
result	41 (100%)	16 of 94
result unit of measurement	32 (74.4%)	6 of 56
assay screening campaign stage	40 (93.0%)	8 of 23
assay footprint	36 (83.7%)	5 of 20
assay kit	9 (20.9%)	5 of 93
physical detection method	42 (97.7%)	11 of 51
detection instrument	26 (60.5%)	9 of 97
perturbagen type	20 (46.5%)	3 of 9

1